NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines
The paper discusses the position of beta-blockers, nebivolol in particular, in the Reappraisal 2009 of ESH/ESC Guidelines on arterial hypertension (AH) management. Nebivolol is not only highly selective towards beta-1 angiotensin II receptors, but also metabolically neutral, and therefore, could be...
Saved in:
Main Author: | V. I. Makolkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2010-12-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2150 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of beta-blockers in the treatment of hypertension in 2018 ESC/ESH guidelines
by: A. O. Konradi, et al.
Published: (2018-12-01) -
New АСС/AHA and ESC/ESH arterial hypertension guidelines
by: E. V. Reznik, et al.
Published: (2018-10-01) -
Pleiotropic activity of antihypertensives in atherothrombogenesis. Nebivolol: increasing possibilities and reducing restrictions
by: M. G. Bubnova
Published: (2008-12-01) -
Nebivolol therapy and reduction of intravascular platelet activity in patients with atrial hypertension and metabolic syndrome
by: I. N. Medvedev
Published: (2006-06-01) -
New targets for arterial hypertension control in patients with coronary heart disease: ESH/ESC guidelines on arterial hypertension management, 2007
by: Yu. A. Karpov
Published: (1970-01-01)